1. Sabaki
A. Hepatitis C virus entry: the early steps in the viral replicative cycle. Virol
J 2009;4:117-125.
2. Organización Panamericana de la Salud OMS. Hepatitis vírica
C. El Control de las Enfermedades Transmisibles. David L Heymann Editor. Décimoctava edición 2005. pág: 343-346. Washington.
3. Seeff L. Natural history of chronic hepatitis
C. Hepatol 2002;36:S35-S46.
4. Levrero M. Viral hepatitis and liver cancer:
the case of hepatitis C. Oncogene 2006;25:3834-3847.
5. Moradipour D, Penin F, Reel C. Replication of
hepatitis C virus. Nat Rev Microbiol 2007;5:453-463.
6. Tang H, Grisé H. Cellular and molecular
biology of HCV infection and hepatitis. Clin Sci (Lond) 2009;117:49-65.
7. Simmonds P. Bukh J. Combat C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C. Virus
genotypes. Hepatology
2005;42:962-973.
8.
Delic D, Nesic Z, Prostran M, et al. Assessment of Chronic Hepatitis C
Virus RNA and Genotypes from 110
Patients with Chronic Hepatitis C Infection in the Serbia. International Journal fo Infectious Diseases.2006. Lisbon. Portugal.
9. Marques
N, Serra J, Saraira de Cunha J, Melico-Silvestre A. HCV Genotype 4: epidemiological and Clinical
Report of 54 Patients. 12th ICID Abstracts. 2006:59012. Pág. S 269. Lisbon. Portugal.
10.
Baseras M, Fernandez M, Sota M, et al. Changes in the Prevalence of
Hepatitis C Virus Genotypes in Northen Spain During a Six-Year
Period. International Congress of
Infectious Diseases. 2006. Abstracts. Lisbon.
Portugal.
11. Icardi G, Sticchi C, Riccio C. Different
Seroprevalence and Molecular Epidemiology Patterns of Hepatitis C Virus
Infection in Italy.
12th ICID. 2006. Abstracts:
S275. Lisbon. Portugal.
12.
Vigani A, Macedo de Oliveira A, Pavan M, et al. Comparative Study Between Hepatitis C Virus Genotypes
1 and 3 in
Patients with Chronic Hepatitis. 12th ICID 2006. Abstracts: S 279. Lisbon. Portugal.
13. Liu
Z, Robida J, Chinnaswamy S, et al. Mutations in the hepatitis C virus
polymerase that increase RNA binding confer resistance to cyclosporine A. Hepatol. 2009;50:25-33.
14.
Newmann A, Lana N, Dahori H, et al. Hepatitis C viral dynamics in vivo
and the antiviral efficacy of interferon.alpha therapy. Science.
1998;282:103-107.
15. Morikawa K, Zhao Z, Date T, et al. The roles of CD 81 and
glicosaminoglycans in the adsorption and uptake of infections HCV particles. J
Med Virol. 2007;79:714-723.
16.
Molina S, Castet V, Fournier-Wirth C, et al. The low density lipoprotein
receptor plays a role in the infection of primary human hepatocytes by
hepatitis C virus. J Hepatol. 2007;46:411-419.
17.
Cormier E, Durso R, Tsamis F, et al. L SIGN (CD 209 L) and DC – SIGN (CD 209)
mediate transinfection of liver cell hepatitis C virus. Proc Natl Acad Sci. USA.
2004;101:14067-14072.
18. Akazawa
D, Date T, Morikawa K, et al. CD 81 expression is important for the
permissiveness of Huh 7 cell clones for heterogeneous hepatitis C virus
infections. J Virol. 2007; 81:5036-5045.
19.
Grove J, Huby T, Stamakky Z, et al. Scavenger receptors BI BII
expression levels modulate hepatitis C virus infectivity. J Virol.
2007;81:3162-3169.
20. Moe
C, Grove J, Harris H, et al. Effect of cell polarization on hepatitis C virus
entry. J Virol. 2008;82:461-470.
21.
Blanchard E, Becouzard S, Gonestain L, et al. Hepatitis C virus entry
depends on clathrin-mediated endocytosis. J Virol. 2006;80:6964-6972.
22.
Lavillette D, Bertoseh B, Noarrisson D, et al. Hepatitis C virus
glycoproteins mediate low pH dependent membrane fusion with liposomes. J Biol
Chem. 2006;281:3909-3017.
23. Bernfield
M, Gotte M, Park P, et al. Functions of all surface heparan sulfate
proteoglycans. Annu Rev Biochem.
1999;68:729-777.
24.
Barth H, Schnober E, Zhang F, et al. Viral and cellular determinants of
the hepatitis C virus envelope-heparan sulfate interaction. J Virol.
2006;80:10579-10590.
25.
Lozach P, Lorat-Jacob H, de Lacroix A, et al. DC-SIGN and L-SIGN are
high affinity binding receptors for hepatitis C virus glycoprotein E2. J Biol
Chem, 2003;278:20358-20360.
26.
Pileri P, Vematsu Y, Campagnoli S, et al. Binding of hepatitis C virus
to CD8. Science. 1998;282:938-941.
27.
Hemler M. Tetraspamin function and associated microdomains. Nat Rev Mol
Cell Biol. 2005;6:801-811.
28.
Cocgueril L, Kuo C, Dubusson J, Levy S. CD 81- dependent binding of
hepatitis C virus E1 E2 heterodimers. J Virol. 2003;77:10677-10683.
29.
Bertaux C, Dragic T. Different
domains of CD 81 mediate distinct stages of hepatitis C virus pseudoparticle
entry. J Virol. 2006;80:4940-4948.
30. Flint M, Maidens C,
Loomis-Price L, et al. Characterizations of hepatitis C virus E glycoprotein
interaction with a putative cellular receptor CD 81. J Virol.
1999;73:6235-6244.
31.
Cornier E, Tsamis F, Kajumo F, et al. CD 81 is an entry coreceptor for
hepatitis C virus. Proc Natl Acad Sci USA. 2004;101:7270-7274.
32.
Rigotti A, Acton S, Kriegar M. The class B scavenger receptors SR-B1 and
CD 36 are receptors for anionil phospholipids. J Biol Chem.
1995;270:16221-16224.
33. Heo
T, Lee S, Barteach B, et al. Hepatitis C virus E2 links soluble human CD 81 and
SR –B 1 protein. Virus Res.. 2006;121:58-64.
34.
Evans M, von Hann T, Tacherne D, et al. Claudin -1 is a hepatitis C
virus co-receptor required for a later step in entry. Nature. 2007;446:801-805.
35.
Ploss A, Evans M, Gaysinskaya V, et al. Human occludin is a hepatitis C
virus entry factor required for infection of mouse cells. Nature.
2009;47:882-886.
36.
Reynolds G, Harris H, Jennings
A, et al. Hepatitis C virus receptor expression in normal and disease liver
tissue. Hepatol. 2008;47:418-427.
37.
Lehermann B. Hepatitis C virus versus innate and adaptive immune
responses: a tale of co-evolution and coexistence. J Clin Invest. 2009;
119:1745-1754.
38. Rubin E, Farber J. El hígado y las vías
biliares. La patología de las hepatitis
aguda y crónica. En: Patología Rubin/Farber.
Editorial Médica Panamericana. Buenos Aires.1998. Pág. 675-679.
39. Rubin E, Farber J. Cirrosis. En: Patología Rubin/Farber. Editorial Médica Panamericana. Buenos
Aires.1998. Pág. 691-693.
40. Organización Panamericana de
la Salud. Hepatitis vírica C. En: El control de las enfermedades transmisibles.
David L. Heymann Editor. Decimonovena edición,
2011. Pág: 397-400. Washington.
41. Seef L. Natural
history of chronic hepatitis C. Hepatol 2006; 36:535-546.
42. Levrero M. Viral hepatitis and liver cancer:
The case of hepatitis C. Oncogene 2006; 215:3834-3847.
43. Rubin E, Farber J. Neoplasias Malignas. Carcinoma hepatocelular. En:
Patología Rubin/Farber. Editorial Médica Panamericana. Buenos Aires.1998. Págs.
719-721.
44. Isada C, Kasten B, Goldman M, et al. Hepatitis C Virus. In: Infectious
Diseases. Layi-Comp. Chicago.1999. Pág. 103-105.
45. Kao
H, Ran F, Guan W, et al. Evaluation of the permanence of the E1 Agen HCV test
for detection of hepatitis C virus infection. J Viral Methods. 2009; (E pub
ahead of print).
46.
McGovern B, Birch B, Bowen M, et al. Improving the diagnosis of Acute
Hepatitis C Virus Infection with Expanded Viral Load Criteria. Clin Infect Dis. 2009; 49:1051-1060.
47. Reyes H,
Navarro P, Hepatitis viral. En:
Enfermedades Infecciosas Virales. Editorial Disinlimed.1998. Pag: 327-365.Caracas.
48.
Resouli M, Ziagen M, Abbasian A, et al. HCV/HIV Co-Infection in Iranian
patients. 12th
ICID 2006. Abstracts. 5900. Pag. 3268. Lisbon. Portugal.
49. Marques
N, Serra J, Saraira de Cunha J, Melico-Silvestre A. Epidemiological, Clinical
and Histological Aspects in Mono-infected and Co-infected (HIV) Patients. 12th ICID 2006.Abstracts: 59011.
Pag. S269. Lisbon.
Portugal.
50. Crockett
S, Keeffe E. Natural history and
treatment of hepatitis B virus and hepatitis C virus co-infection. Ann Clin
Microbiol Antimicrob 2005;4:13-18.
51. Lee
W. Hepatitis virus infection. N Engl J Med. 1997;227:1733-1745.
52.
Centers for Diseases Control and Prevention. Recommendation for prevention and control of
hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR
1998;47:1-39.
53. Dovi
K, Singh N, Mara J, et al. Seroprevalence of Hepatitis B vírus and Hepatitis C vírus among Hepatic
Disorders and Injecting Drugs Users in Manipur.
A Preliminary Report. Indian J Med Microbiol. 2004;22:136-137.
54. Pallas J, Farinas-Alvarez C, Prieto D,
Delgado-Rodriguez M. Co-infections by HIV, hepatitis B and hepatitis C in
imprisoned injecting drug users. Eur
Epidemiol.1999;15:699-704.
55.
Reddy G, Dakshinamurthy K, Necladresad P, et al. Prevalence of HBV and HCV dual infection in
patients on hemodialysis. Indian J Med Microbiol. 2005;23:41-43.
56. Aroldi
A, Lampertico P, Montagnino G, et al. Natural history of hepatitis B and C in renal allograft recipients. Transplantation 2005; 79: 1132-1136
57. Kabinowska-Nowak
A, Bociaga-Lasik M, Garlicki A, Skaware P. Prevalence of hepatotropic viruses
HBV and HCV in HIV infected patients from Southern region of Poland. Acta
Virol. 2000; 44: 23-28
58. Irshad
M, Peter S. Spectrum of viral hepatitis in thalassemic children receiving multiple
blood transfusions. Indian J Gastroenterol.
2002;21:183-184.
59. Saravanam S, Vijayakumar V, Nandakumar S,
et al. Hepatitis B vírus
and hepatitis C vírus dual infection, among patients with chronic liver
disease. J Microbiol Immnunol Infect. 2009;4:122-128.
60. Liaw Y. Concurrent hepatitis B and C virus: is hepatitis C virus
stronger? J Gastroenterol Hepatol. 2001;16:597-598.
61. Jardi R, Rodríguez F, Buti M, et al. Role hepatitis B, C and D viruses in dual and
triple infection influence of viral genotypes and hepatitis B precore and viral
core promoter mutations in viral replicative interference. Hepatol.
2001;34:404-410.
62. Crespo J, Lozano J, de la
Cruz F, et al. Prevalence and significance of hepatitis C
viremia in chronic active hepatitis B. Am J Gastroenterol. 2004;8:1147-1151.
63.
Zarski J, Bohn B, Bastic A, et al.
Characteristics of patients with dual infection by hepatitis B and C
viruses. Hepatol. 1998;28:27-33.
64. Kim
YK, Kim Y, Shimm S. Thoracic complications of liver cirrhosis; radiologic
findings. Radiograph. 2009;29:825-837.
65.
Tosti M, Mariano A, Blanco E, et al.
Extra-hepatic Cancer Incidence Among Patients with Hepatitis C Virus
Infections. A cohort Study. Int J
Infect Dis. 2006.Abstracts. 5901. Pág:3268. Lisbon. Portugal.
66. Organización Panamericana de la Salud. OPS. Tratamiento de las
Enfermedades Virales. En: Tratamiento de las Enfermedades Infecciosas. 3ª Ed.
2008. Pág. 200-217. Washington.
67.
Pisula A, Janczewska-Kazek E, Smalyk A, et al. Re- therapy with Pegylated interferon and
Ribavirin in Patients with Chronic Hepatitis Previously Treated with Interferon
Alfa and Ribavirin. 12th
ICID. 2006. Abstracts. Vol 10. S 272. Lisbon. Portugal.
